Press enter to begin your search

Open Orphan PLC - Publication of positive results

ORPH
Wed, 11 Mar 2020, 07:00 GMT

Cathal Friel, Executive Chairman of Open Orphan and Doctor Andrew Catchpole, Chief Scientist at hVIVO discuss the publication of positive results of a Phase IIb field study of FLU-v 003 and it's significance as well as the new hVIVO contract signed with a European Biotech Company.

Cathal Friel
Executive Chairman
ORPH
Dr. Andrew Catchpole
Chief Scientist
ORPH
5e677b0f9672d83b987783d4
SHOW MORE
FROM THIS COMPANY
Open Orphan PLC - Publication of positive results
ORPH Wed, 11 Mar 2020, 07:00 GMT

Open Orphan was founded in 2017, with the goal of becoming Europe’s leading rare disease and orphan drug-focused pharma services company by a management team with extensive industry and financial expertise.

Industry: Health Care

Contact: +353 (01) 6440007
Dublin 2, Ireland
https://www.openorphan.com

Cathal Friel, Executive Chairman of Open Orphan and Doctor Andrew Catchpole, Chief Scientist at hVIVO discuss the publication of positive results of a Phase IIb field study of FLU-v 003 and it's significance as well as the new hVIVO contract signed with a European Biotech Company.

Cathal Friel
Executive Chairman
Dr. Andrew Catchpole
Chief Scientist
POWERED BY